{
  "slug": "public-health-intervention-roi",
  "title": "Public Health Intervention ROI Predictor",
  "seo": {
    "title": "Public Health Intervention ROI Calculator | Predict Disease Burden, Cost Savings & QALYs",
    "description": "Estimate the Return on Investment for public health initiatives. Calculate averted disease burden (DALYs), healthcare cost savings, and quality-of-life improvements (QALYs) to inform policy and funding decisions, crucial for societal well-being."
  },
  "inputs": [
    {
      "id": "interventionCost",
      "label": "Total Intervention Cost",
      "type": "number",
      "placeholder": "e.g., 5000000 for $5M",
      "required": true,
      "step": 10000
    },
    {
      "id": "targetPopulation",
      "label": "Size of Target Population",
      "type": "number",
      "placeholder": "e.g., 100000",
      "required": true,
      "step": 1000
    },
    {
      "id": "interventionDuration",
      "label": "Intervention Duration (Years)",
      "type": "number",
      "placeholder": "e.g., 5",
      "required": true,
      "step": 1
    },
    {
      "id": "baselineDiseasePrevalence",
      "label": "Baseline Disease Prevalence in Target Population (%)",
      "type": "number",
      "placeholder": "e.g., 10 for 10%",
      "required": true,
      "step": 0.1
    },
    {
      "id": "interventionEffectiveness",
      "label": "Intervention Effectiveness (Reduction in Incidence/Prevalence, %)",
      "type": "number",
      "placeholder": "e.g., 25 for 25% reduction",
      "required": true,
      "step": 0.1
    },
    {
      "id": "averageCostPerCase",
      "label": "Average Healthcare Cost Per Disease Case (USD)",
      "type": "number",
      "placeholder": "e.g., 1500",
      "required": true,
      "step": 10
    },
    {
      "id": "averageDALYburdenPerCase",
      "label": "Average DALY Burden Per Disease Case (DALYs)",
      "type": "number",
      "placeholder": "e.g., 0.5",
      "required": true,
      "step": 0.01
    },
    {
      "id": "averageQALYgainPerCaseAverted",
      "label": "Average QALY Gain Per Disease Case Averted (QALYs)",
      "type": "number",
      "placeholder": "e.g., 0.75",
      "required": true,
      "step": 0.01
    },
    {
      "id": "societalValuePerDALY",
      "label": "Societal Value Per DALY Averted (USD)",
      "type": "number",
      "placeholder": "e.g., 50000",
      "required": true,
      "step": 1000
    },
    {
      "id": "discountRate",
      "label": "Annual Discount Rate for Future Benefits (%)",
      "type": "number",
      "placeholder": "e.g., 3 for 3%",
      "required": true,
      "step": 0.1
    }
  ],
  "outputs": [
    {
      "id": "netROI",
      "label": "Net Return on Investment",
      "unit": "USD",
      "precision": 0
    },
    {
      "id": "roiPercentage",
      "label": "ROI Percentage",
      "unit": "%",
      "precision": 2
    },
    {
      "id": "totalAvertedDALYs",
      "label": "Total Averted DALYs (Discounted)",
      "unit": "DALYs",
      "precision": 2
    },
    {
      "id": "totalHealthcareSavings",
      "label": "Total Healthcare Cost Savings (Discounted)",
      "unit": "USD",
      "precision": 0
    },
    {
      "id": "totalQALYsGained",
      "label": "Total QALYs Gained (Discounted)",
      "unit": "QALYs",
      "precision": 2
    },
    {
      "id": "costPerDALY",
      "label": "Cost Per DALY Averted",
      "unit": "USD/DALY",
      "precision": 0
    },
    {
      "id": "costPerQALY",
      "label": "Cost Per QALY Gained",
      "unit": "USD/QALY",
      "precision": 0
    }
  ],
  "formula": "function calculate({\n  interventionCost,\n  targetPopulation,\n  interventionDuration,\n  baselineDiseasePrevalence,\n  interventionEffectiveness,\n  averageCostPerCase,\n  averageDALYburdenPerCase,\n  averageQALYgainPerCaseAverted,\n  societalValuePerDALY,\n  discountRate\n}) {\n  // Input validation and normalization\n  interventionCost = Math.max(0, interventionCost || 0);\n  targetPopulation = Math.max(0, targetPopulation || 0);\n  interventionDuration = Math.max(1, interventionDuration || 1); // Duration must be at least 1 year\n  baselineDiseasePrevalence = Math.min(100, Math.max(0, baselineDiseasePrevalence || 0));\n  interventionEffectiveness = Math.min(100, Math.max(0, interventionEffectiveness || 0));\n  averageCostPerCase = Math.max(0, averageCostPerCase || 0);\n  averageDALYburdenPerCase = Math.max(0, averageDALYburdenPerCase || 0);\n  averageQALYgainPerCaseAverted = Math.max(0, averageQALYgainPerCaseAverted || 0);\n  societalValuePerDALY = Math.max(0, societalValuePerDALY || 0);\n  discountRate = Math.max(0, discountRate || 0);\n\n  const annualDiseasePrevalenceRate = baselineDiseasePrevalence / 100;\n  const annualInterventionEffectivenessRate = interventionEffectiveness / 100;\n  const annualDiscountFactor = discountRate / 100;\n\n  let totalDiscountedHealthcareSavings = 0;\n  let totalDiscountedMonetizedDALYBenefits = 0;\n  let totalDiscountedAvertedDALYs = 0;\n  let totalDiscountedQALYsGained = 0;\n\n  // Calculate annual averted cases and benefits, then discount over duration\n  for (let year = 1; year <= interventionDuration; year++) {\n    const discountMultiplier = 1 / Math.pow(1 + annualDiscountFactor, year);\n\n    // Annual cases averted calculation (assuming effectiveness is applied to the *prevalent* cases each year)\n    // This simplifies annual disease burden reduction without complex epidemiological modeling.\n    const annualCasesAverted = targetPopulation * annualDiseasePrevalenceRate * annualInterventionEffectivenessRate;\n\n    const annualHealthcareSavings = annualCasesAverted * averageCostPerCase;\n    const annualAvertedDALYs = annualCasesAverted * averageDALYburdenPerCase;\n    const annualQALYsGained = annualCasesAverted * averageQALYgainPerCaseAverted;\n    const annualMonetizedDALYBenefits = annualAvertedDALYs * societalValuePerDALY;\n\n    totalDiscountedHealthcareSavings += annualHealthcareSavings * discountMultiplier;\n    totalDiscountedMonetizedDALYBenefits += annualMonetizedDALYBenefits * discountMultiplier;\n    totalDiscountedAvertedDALYs += annualAvertedDALYs * discountMultiplier;\n    totalDiscountedQALYsGained += annualQALYsGained * discountMultiplier;\n  }\n\n  const totalBenefits = totalDiscountedHealthcareSavings + totalDiscountedMonetizedDALYBenefits;\n  const netROI = totalBenefits - interventionCost;\n\n  let roiPercentage = 0;\n  if (interventionCost > 0) {\n    roiPercentage = (netROI / interventionCost) * 100;\n  } else if (totalBenefits > 0) {\n    roiPercentage = Infinity; // Infinite ROI if cost is zero and benefits exist\n  }\n\n  let costPerDALY = Infinity;\n  if (totalDiscountedAvertedDALYs > 0) {\n    costPerDALY = interventionCost / totalDiscountedAvertedDALYs;\n  }\n\n  let costPerQALY = Infinity;\n  if (totalDiscountedQALYsGained > 0) {\n    costPerQALY = interventionCost / totalDiscountedQALYsGained;\n  }\n\n  return {\n    netROI: netROI,\n    roiPercentage: roiPercentage,\n    totalAvertedDALYs: totalDiscountedAvertedDALYs,\n    totalHealthcareSavings: totalDiscountedHealthcareSavings,\n    totalQALYsGained: totalDiscountedQALYsGained,\n    costPerDALY: costPerDALY,\n    costPerQALY: costPerQALY\n  };\n}",
  "summary": "This tool helps policymakers, public health officials, and researchers quantify the economic and health benefits of various public health interventions. By projecting averted disease burden, healthcare cost savings, and quality-of-life improvements, it provides a robust estimate of the Return on Investment (ROI) for strategic planning and resource allocation, especially vital in contexts where public health infrastructure is challenged.",
  "cta": "Calculate the ROI for your Public Health Intervention",
  "faq": [
    {
      "q": "What is Return on Investment (ROI) in the context of public health?",
      "a": "ROI in public health measures the economic and health benefits generated by an intervention relative to its cost. It quantifies how much 'value'—in terms of averted healthcare costs, improved quality of life, and reduced disease burden—is created for every dollar invested. This predictor calculates Net ROI (total benefits minus costs) and ROI percentage (Net ROI / Costs * 100)."
    },
    {
      "q": "Why are DALYs (Disability-Adjusted Life Years) and QALYs (Quality-Adjusted Life Years) important for this calculation?",
      "a": "DALYs and QALYs are critical metrics for comprehensively assessing the health impact of interventions. DALYs quantify the total burden of disease, representing years of life lost due to premature mortality and years lived with disability. Averting DALYs means reducing this burden. QALYs measure the quality and quantity of life, where 1 QALY equals one year of perfect health. Gaining QALYs signifies improved health and well-being. These metrics allow for a standardized comparison of interventions across different diseases and outcomes."
    },
    {
      "q": "How is the 'Societal Value Per DALY Averted' determined?",
      "a": "The 'Societal Value Per DALY Averted' is a crucial economic input that monetizes the health benefits of preventing one DALY. Its value can vary significantly based on national economic contexts, ethical frameworks, and policy decisions. It often reflects a society's willingness-to-pay for health improvements, derived from methods like contingent valuation or human capital approaches. Users should input a value consistent with the guidelines or prevailing estimates in their specific region or organization."
    },
    {
      "q": "What is the 'Annual Discount Rate' and why is it used?",
      "a": "The annual discount rate accounts for the time preference for money and health. A dollar or a health benefit received today is generally valued more highly than the same dollar or benefit received in the future. Discounting converts future costs and benefits to their present value, allowing for a fair comparison of interventions with different time horizons. A typical discount rate for public health interventions might range from 3% to 5%."
    },
    {
      "q": "Does this tool account for indirect benefits like increased productivity or educational attainment?",
      "a": "While the primary calculation focuses on direct healthcare cost savings and the monetized value of DALYs averted, which implicitly captures some productivity gains (as healthier individuals are more productive), it does not explicitly quantify separate indirect benefits like enhanced educational outcomes or specific economic growth. These are complex to model and often require more granular data, but users can consider a higher 'Societal Value Per DALY Averted' to broadly encompass these broader societal impacts if justified by their valuation methodology."
    },
    {
      "q": "What are the key limitations of this ROI predictor?",
      "a": "This tool provides an estimate based on aggregated inputs and a simplified model. Key limitations include reliance on accurate input data (e.g., prevalence, effectiveness), the inherent subjectivity in assigning a monetary value to DALYs/QALYs, and its inability to capture all nuanced social, ethical, or equity considerations. It assumes a linear impact of the intervention and doesn't account for complex epidemiological dynamics, herd immunity effects, or unforeseen externalities. It's best used as a decision-support tool, not a definitive final answer."
    },
    {
      "q": "How can I ensure the accuracy of the results?",
      "a": "The accuracy of the results is directly dependent on the quality and reliability of your input data. Utilize evidence-based estimates for disease prevalence, intervention effectiveness (from randomized controlled trials, systematic reviews, meta-analyses), and established economic parameters for healthcare costs and DALY/QALY valuations. Sensitivity analysis (varying inputs within a reasonable range) is also highly recommended to understand how robust your ROI estimate is to uncertainty."
    },
    {
      "q": "Who is the target audience for this Public Health Intervention ROI Predictor?",
      "a": "This tool is designed for a diverse audience, including public health officials and ministries of health seeking to justify funding, non-governmental organizations (NGOs) evaluating program efficacy, academic researchers conducting cost-effectiveness analyses, and healthcare administrators making resource allocation decisions. It's particularly useful for those in environments facing significant public health challenges and constrained resources, where demonstrating value is paramount."
    }
  ],
  "tags": [
    "health",
    "public health",
    "ROI",
    "economic evaluation",
    "cost-effectiveness",
    "DALY",
    "QALY",
    "disease prevention",
    "health policy",
    "resource allocation",
    "evidence-based decision making"
  ],
  "related": [
    "vaccination-program-cost-benefit-calculator",
    "chronic-disease-management-roi-estimator",
    "maternal-child-health-program-impact-predictor"
  ],
  "article": [
    {
      "heading": "The Importance of Public Health Intervention ROI Predictor in Modern Context",
      "body": "In an era marked by complex global challenges, from climate change to persistent social inequities and political instability, public health stands at the forefront of human well-being. The impact of societal challenges, such as repression in certain regions leading to mass displacement, breakdown of healthcare systems, and widespread psychological trauma, underscores the fragility of public health infrastructure and the urgent need for effective interventions. In such contexts, and even in more stable ones, resources for public health are perpetually finite, making the ability to demonstrate quantifiable returns on investment (ROI) not just a desideratum, but a moral and strategic imperative.\n\nThe Public Health Intervention ROI Predictor emerges as an indispensable tool in this landscape. It moves beyond anecdotal evidence or general good intentions, providing a rigorous, data-driven framework to evaluate the true value of health initiatives. Whether it's a vaccination campaign, a maternal health program, a sanitation project, or a mental health support system, understanding its economic and health benefits is crucial. This predictor empowers policymakers and public health professionals to make informed decisions, ensuring that scarce funds are allocated to interventions that yield the greatest positive impact on populations.\n\nThe 'why' behind this tool is deeply rooted in principles of accountability and efficacy. Public health initiatives, by their very nature, are often preventative and long-term, making their benefits less immediately visible than acute care. This can make them vulnerable to budget cuts or underfunding. By quantifying averted disease burden (measured in DALYs), healthcare cost savings, and quality-of-life improvements (measured in QALYs), the ROI predictor provides a compelling narrative that translates complex health outcomes into understandable, economic terms. This is particularly vital when competing for funding against other sectors or when advocating for sustained investment in health programs.\n\nMoreover, the tool fosters transparency and strengthens public trust. When public funds are invested, citizens and stakeholders have a right to understand the rationale and the expected dividends. An ROI predictor offers a clear, structured way to articulate these benefits, promoting a culture of evidence-based policy-making. It enables a shift from reactive crisis management to proactive health promotion, building resilient communities better equipped to withstand the myriad challenges of the 21st century. In environments where political stability is fragile or where health systems are under immense strain, the strategic deployment of resources, guided by clear ROI projections, can literally save lives and rebuild societal foundations."
    },
    {
      "heading": "In-Depth Technical Guide: How the Calculation Works",
      "body": "The Public Health Intervention ROI Predictor employs a systematic methodology to convert various input parameters into comprehensive output metrics. At its core, the calculation revolves around projecting the number of disease cases averted and then translating these averted cases into tangible health and economic benefits, discounted over time.\n\n1.  **Annual Cases Averted**: The first step involves estimating the annual number of disease cases that the intervention is expected to prevent. This is calculated by taking the `targetPopulation`, multiplying it by the `baselineDiseasePrevalence` (converted to a decimal), and then by the `interventionEffectiveness` (also as a decimal). This gives us the number of individuals who would have contracted the disease but are now spared due to the intervention each year.\n\n2.  **Annual Benefits Calculation**: For each averted case, we then quantify three key benefits:\n    *   **Healthcare Cost Savings**: By multiplying the `annualCasesAverted` by the `averageCostPerCase`, we derive the direct healthcare expenditures avoided. This includes treatment costs, hospitalization, and medication that would otherwise have been incurred.\n    *   **DALYs Averted**: The `annualCasesAverted` are multiplied by the `averageDALYburdenPerCase`. This provides a measure of the total disability-adjusted life years prevented, representing a reduction in the overall disease burden on the population.\n    *   **QALYs Gained**: Similarly, `annualCasesAverted` are multiplied by the `averageQALYgainPerCaseAverted`. This quantifies the improvement in the quality and length of life for individuals who avoid the disease.\n\n3.  **Monetization of Health Outcomes**: To integrate DALYs averted into an economic ROI calculation, they are monetized. The `annualAvertedDALYs` are multiplied by the `societalValuePerDALY` input. This converts the health benefit of reduced disease burden into an equivalent monetary value, allowing for its inclusion in the total economic benefits.\n\n4.  **Discounting Future Benefits**: A critical component for long-term interventions is the application of the `annualDiscountRate`. Both the economic benefits (healthcare savings and monetized DALYs) and the health outcomes (DALYs and QALYs) accrue over the `interventionDuration`. Due to the time value of money and health, benefits received in future years are worth less than those received today. The formula iteratively calculates the benefits for each year of the intervention's duration and then applies a discount factor `(1 / (1 + discountRate/100)^year)` to bring these future benefits to their present value. These discounted annual benefits are summed up to yield total discounted benefits over the entire intervention period.\n\n5.  **Total Economic Benefits and Net ROI**: The total discounted healthcare savings are added to the total discounted monetized DALY benefits to arrive at the `totalBenefits`. The `netROI` is then calculated by subtracting the `interventionCost` from these `totalBenefits`. A positive Net ROI indicates that the intervention generates more value than it costs.\n\n6.  **ROI Percentage**: The `roiPercentage` is derived by dividing the `netROI` by the `interventionCost` and multiplying by 100. This provides a relative measure of return, indicating how many dollars of benefit are generated for every dollar invested. Edge cases where `interventionCost` is zero are handled to prevent division by zero, resulting in an 'Infinite' ROI if benefits are positive.\n\n7.  **Cost-Effectiveness Ratios**: The tool also calculates `costPerDALY Averted` and `costPerQALY Gained`. These ratios are derived by dividing the `interventionCost` by the `totalDiscountedAvertedDALYs` and `totalDiscountedQALYsGained`, respectively. These metrics are crucial for comparing interventions based on their efficiency in generating health outcomes, providing valuable context even if a positive monetary ROI is not achieved. An infinitely high cost per DALY/QALY signifies that no health benefit was achieved for the investment, or no health outcome was reported (zero DALYs/QALYs averted/gained)."
    },
    {
      "heading": "Real-World Application Scenarios",
      "body": "The Public Health Intervention ROI Predictor offers practical utility across various sectors and decision-making contexts. Here are a few detailed scenarios:\n\n**Scenario 1: Government Health Ministry Strategic Planning (National Immunization Program)**\n\n*   **Situation**: The Ministry of Health in a developing nation is deciding on resource allocation between two major initiatives: expanding a national measles vaccination program to remote rural areas or launching a new hypertension screening and management program in urban centers. Both are crucial, but funding is limited.\n*   **Application**: The ministry's planning team uses the ROI predictor. For the measles vaccination program, they input the estimated cost of reaching additional remote populations, the target population size, the current measles prevalence, the high effectiveness of the vaccine, the average healthcare cost of treating measles cases (including complications), and the DALY/QALY burden of the disease. For hypertension, they input similar parameters for screening, medication, and lifestyle intervention costs, target population, prevalence, effectiveness in reducing complications, and the associated DALY/QALY burden. They apply a national discount rate and a standardized societal value per DALY.\n*   **Outcome**: The predictor reveals that while both programs offer significant benefits, the expanded measles vaccination program yields a higher ROI due to its lower cost per person, high effectiveness in preventing severe illness, and significant DALYs averted from a highly prevalent and debilitating disease in those regions. This data empowers the ministry to secure funding for the vaccination program, demonstrating clear economic and health dividends, while also planning for the hypertension program in subsequent budget cycles with a more precise understanding of its future potential ROI.\n\n**Scenario 2: Non-Governmental Organization (NGO) Program Evaluation (Water, Sanitation, and Hygiene - WASH Project)**\n\n*   **Situation**: An international NGO operates in several sub-Saharan African countries, implementing WASH projects to reduce diarrheal diseases. They need to evaluate a recent project in a specific district to report to donors and refine future interventions.\n*   **Application**: The NGO team inputs the total cost of installing boreholes, latrines, and conducting hygiene education in the district (interventionCost), the district's population (targetPopulation), the project's duration, and the baseline prevalence of diarrheal diseases. They gather data on the observed reduction in diarrheal disease incidence (interventionEffectiveness), the average cost of treating a diarrheal episode (averageCostPerCase), and the estimated DALY and QALY burden per episode from local epidemiological studies. A regional societal value per DALY and a relevant discount rate are also applied.\n*   **Outcome**: The calculator shows a substantial positive ROI for the WASH project, primarily driven by significant averted DALYs and healthcare savings from reduced diarrheal episodes. The cost-per-DALY-averted is found to be highly favorable, reinforcing the project's cost-effectiveness. This robust data enables the NGO to demonstrate impactful use of donor funds, justify requests for further funding, and identify best practices for scaling similar projects in other vulnerable communities.\n\n**Scenario 3: Hospital System Community Health Initiative (Diabetes Prevention Program)**\n\n*   **Situation**: A large integrated hospital system in a developed country is considering launching a community-based diabetes prevention program for at-risk adults, aiming to reduce future healthcare utilization and improve population health.\n*   **Application**: The hospital system's population health department uses the predictor. They input the estimated cost of the 3-year program (staffing, educational materials, community outreach), the size of the at-risk population identified through screenings, and the baseline prevalence of pre-diabetes or early-stage diabetes. They leverage evidence from similar programs for intervention effectiveness (e.g., % reduction in progression to full-blown diabetes), and internal data for average healthcare costs for managing diabetes complications (e.g., amputations, kidney failure) and the associated DALY/QALY burden. A societal value per DALY (aligned with national health economic guidelines) and a discount rate are also used.\n*   **Outcome**: The analysis reveals a positive long-term ROI, driven significantly by averted chronic disease management costs and improved quality of life for participants. The cost-per-QALY-gained is well within acceptable thresholds, making a strong case for investment. This provides the executive leadership with the evidence needed to approve the program, recognizing its potential to not only improve community health but also to reduce future financial burdens on the health system by shifting from treatment to prevention."
    },
    {
      "heading": "Advanced Considerations and Potential Pitfalls",
      "body": "While the Public Health Intervention ROI Predictor offers a powerful framework for decision-making, its effective application requires a nuanced understanding of advanced considerations and potential pitfalls.\n\n**1. Data Quality and Uncertainty**: The accuracy of ROI estimates is critically dependent on the quality of input data. Estimates for baseline disease prevalence, intervention effectiveness, and average costs per case can vary widely based on geographical location, demographic groups, and data collection methodologies. Relying on outdated, unrepresentative, or methodologically weak data can lead to misleading ROI projections. Conducting sensitivity analyses by varying key input parameters (e.g., effectiveness from ±5% to ±20%) is crucial to understand the robustness of the results and identify the most influential variables.\n\n**2. Ethical and Equity Considerations in Valuation**: The concept of 'Societal Value Per DALY Averted' or 'Cost Per QALY Gained' raises profound ethical questions. How does a society truly value a year of healthy life, particularly for different populations or disease states? These values can be contentious, and their application might inadvertently lead to interventions favoring certain demographic groups or diseases over others, potentially exacerbating health inequities. It's essential to ensure that the chosen societal value aligns with broader ethical principles and is transparently justified, avoiding a purely utilitarian approach that overlooks the needs of vulnerable or marginalized populations.\n\n**3. Long-Term vs. Short-Term Impacts**: Many public health interventions, especially preventative ones, yield their most significant benefits over extended periods, sometimes decades. The `interventionDuration` and `discountRate` inputs are crucial here. An excessively short duration might underestimate true ROI, while a very long duration could make benefits appear negligible if a high discount rate is applied. Policymakers must balance the need for immediate results with the understanding of long-term health gains, and choose an appropriate duration and discount rate that reflects the true time horizon of benefits.\n\n**4. Unintended Consequences and Externalities**: This predictor, like many simplified models, primarily focuses on direct, intended benefits. However, public health interventions can have complex, sometimes unforeseen, consequences. For example, successful disease eradication might lead to resource shifts away from other vital areas, or new health challenges might emerge. Furthermore, positive externalities, such as improved social cohesion or increased trust in public institutions, are difficult to quantify but contribute significantly to societal well-being. A comprehensive evaluation should ideally consider these broader impacts beyond the immediate scope of the calculation.\n\n**5. Political Will and Implementation Challenges**: Even with a high projected ROI, an intervention's success ultimately hinges on political will, effective governance, and robust implementation. Factors like corruption, bureaucratic inefficiencies, lack of community engagement, or resistance to change can severely impede an intervention's real-world effectiveness, regardless of its theoretical ROI. The predictor provides a quantitative basis for decision-making but cannot substitute for strong leadership, community participation, and adaptive management in navigating the complexities of public health practice.\n\nIn conclusion, while the Public Health Intervention ROI Predictor is an invaluable tool for economic evaluation, it should be used in conjunction with qualitative data, ethical reviews, and a deep understanding of the socio-political context. It serves as a powerful guide, but not a sole determinant, in the challenging and critical field of public health."
    }
  ]
}
